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Abstract 
 
Objective:  The objective of this selective EBM review is to determine whether or not in 
adult patients with diabetic macular edema intravetrial bevacizumab injections are more 
effective than laser therapy at improving best-corrected visual acuity. 
 
Study Design: Review of three English language non-blinded randomized control trials 
from 2010 and 2012.  
 
Data Sources: Non-blinded randomized control trials comparing intravetrial 
bevacizumab injections to macular laser therapy found using Pubmed and EBSCOhost 
web databases. All articles were published in peer-reviewed journals.  
 
Outcomes Measured: The primary outcome of best-corrected visual acuity (BCVA) was 
measured using the Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol 
and visual acuity charts and Snellen visual acuity charts at 6, 12, and 24 months in their 
respective studies.  
 
Results: When comparing macular laser therapy to intravetrial bevacizumab injections 
the patients receiving the injections had a statistically significant (P > 0.05) increase in 
BCVA at 1, 12, and 24-month time points. At 24 months the proportion of patients who 
gained 10 or more letters was 49% for the bevacizumab group and 7% in the laser 
therapy group.  
 
Conclusion: Although macular laser therapy is the current standard of care for diabetic 
macular edema (DME), it has been proven to produce inferior clinical outcomes alone 
when compared with intravetrial bevacizumab injections and other monoclonal 
antibodies. Long-term use of bevacizumab should be considered as an initial treatment 
modality for DME to not only halt vision loss, but restore vision as well.  
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Introduction  
Type II diabetes is a metabolic disorder characterized by inappropriate 
hyperglycemia due to the occurrence of insulin resistance at a cellular level and 
ultimately inadequate insulin secretion from the pancreas.  The cornerstone of treatment 
consists of strict glycemic control via insulin or oral agents as well as aggressive 
hypertension and hyperlipidemia treatment and monitoring. When diabetes is poorly 
controlled it can lead to an array of micro and macro vascular complications including 
retinopathy, neuropathy, and coronary artery disease.  
One such complication, diabetic macular edema, occurs when there is retinal 
thickening due to micro vascular changes compromising the blood-retinal barrier. This 
causes an increased permeability of the capillaries leading to leakage of plasma into the 
surrounding retina causing edema. 1 Vascular endothelial growth factor (VEGF) and other 
inflammatory markers such as cytokines also play a role in retinal edema.1  
Diabetes is a leading cause of blindness, with diabetic retinopathy becoming the 
leading cause of preventable blindness in the United States.  This amounts to countless 
visits to primary care providers per year and an increase in specialist appointments with 
DME patients encountering the ophthalmologist 7.9 times per year. 4 This translates into 
a 31% increase in healthcare costs for this patient population already heavily burdened by 
their chronic condition.3 The overall result is increased heath care spending is illustrated 
by data that the total estimated cost of diabetes in 2012 was $245 billion.2 
The current treatment paradigm for diabetic macular edema is to optimize 
glycemic and hypertensive control to preserve visual acuity and begin laser 
photocoagulation therapy when ophthalmic exam reveals abnormalities. Laser therapy is 
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initiated when the disease process is clinically significant classified by retinal thickening 
and hard exudates on funduscopic exam.8 Adjunct medications include intravitreal 
triamcinolone acetonide injections, anti-VEGF therapy in the form of monoclonal 
antibodies, and intravitreal corticosteroid injections.8 
Currently laser photocoagulation therapy is the standard of care, but this 
procedure only halts further vision loss from the time of diagnosis, which is usually after 
significant damage has occurred. Other treatment modalities are aimed at restoring vision 
lost prior to diagnosis and can be utilized earlier in the disease process to reclaim visual 
acuity and quality of life.  
Objective  
The objective of this systematic review is to determine whether or not in adult 
patients with diabetic macular edema intravetrial bevacizumab injections are more 
effective than laser therapy at improving best-corrected visual acuity.  
Methods  
All three studies selected for this review focused on a population of adult patients 
greater than 40 years of age with a diagnosis of diabetic macular edema. The 
interventions under investigation are repeated intravetrial bevacizumab injections versus 
the comparison group of laser photocoagulation therapy. The outcome measured in all 
three studies was best-corrected visual acuity. Two of the studies utilized the Early 
Treatment of Diabetic Retinopathy Study (ETDRS) protocol, which is the gold standard 
for visual acuity measurement for clinical trials. The third study used a traditional Snellen 
visual acuity chart and the results were reported in logMAR notation.  All three studies 
chosen for this review were non-blinded randomized controlled trials.  
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The author completed a search during the time period of January through 
February of 2013 using Pubmed and EBSCOhost web databases. The key words used 
during the search were “Diabetic Macular Edema” and “Bevacizumab” and “Laser 
Therapy”.  All three articles were published in English between 2010 and 2012 in peer-
reviewed journals.  The studies were selected based on their relevance to the clinical 
question posed and focused on outcomes that were patient oriented (POEMS; patient 
outcome evidence that matters).  Only articles that investigated laser therapy and 
intravetrial bevacizumab injections were utilized and had to exclude other treatment 
modalities.  
Inclusion criteria include studies that were randomized, controlled, prospective, 
and focused on patient oriented outcomes (POEMS). Exclusion criteria were trials with 
patients less than 18 years of age, macular edema due to causes other than diabetes, and 
primary measurements of disease oriented outcomes (DOE’s).  Summary of statistics 
reported or used include P-values, RBI, ABI, NNT, paired t-test, and change from 
baseline.  
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Table 1: Demographics and Characteristics of Included Studies  
 
Study  Type  # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria  W/D Interventions 
Michaelides5 
(2010) 
RCT 80 40-86  M or F >18 yo, 
DM, (BCVA) in 
the study eye 
between 35 and 
69 ETDRS letters 
at 4 mm, DME 
with CMT on 
OCT >270 micro 
meters, at least 1 
prior MLT 
 
Macular ischemia, 
macular edema 
due to a cause 
other than DME, 
any tx for DME in 
preceding 3 
months,  
significant 
extraocular 
disease, A1c>11% 
2 Laser therapy or    
intravetrial 
bevacizumab 
injections  
Rajendram6 
(2012) 
RCT 80 40-86  M or F >18 yo, 
DM, (BCVA) in 
the study eye 
between 35 and 
69 ETDRS letters 
at 4 mm, DME 
with CMT on 
OCT >270 micro 
meters, at least 1 
prior MLT, no 
anti-VEGF tx in 
fellow eye in 
previous 3 months 
 
Macular ischemia, 
macular edema 
due to a cause 
other than DME, 
any tx for DME in 
preceding 3 
months,  
significant 
extraocular 
disease, A1c>11% 
19 Laser therapy or  
intravetrial 
bevacizumab 
injections 
Solaiman7 
(2010) 
RCT 42 42-72 CSME with CMT 
on OCT >350 
micro meters, no 
hx injection, 
surgical 
intervention, or 
laser therapy  
Macular ischemia, 
history intraocular 
surgery in the 
previous year, 
opacity of the 
optical media as 
cataract or 
vitreous 
hemorrhage 
0 Laser therapy or  
intravetri
al 
bevacizumab 
injections 
 
 
Outcomes Measured 
In all three studies the primary outcome measured was best-corrected visual 
acuity. In two of the studies the Early Treatment of Diabetic Retinopathy Study (ETDRS) 
protocol was chosen which uses an ETDRS visual acuity chart that has a more linear 
progression than standard eye charts. The visual acuity results were reported in letter 
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count notation. The third study utilized a traditional Snellen chart and reported their 
results in LogMAR notation.  
Results 
Two of the randomized controlled trials, 12 and 24-month data reports for the 
“BOLT Study”, evaluated the efficacy of intravetrial bevacizumab injections versus 
macular laser therapy in adult patients with clinically significant diabetic macular edema 
with the use of dichotomous data. The third trial made the same comparison with the use 
of continuous data.  
In Michaelides et al 80 eyes were stratified according to BCVA and randomized 
into treatment and comparison groups.  All participants had no clinically significant 
differences at baseline with regards to demographic characteristics, BP, HbA1c, BCVA, 
and retinopathy grading. Only duration of DME varied between the two groups with 
mean duration in months of 162 in the bevacizumab group and 177 in the laser group.  In 
the laser arm 38 eyes underwent macular laser treatment at baseline and were followed 
every four months with a final visit at 12 months. Patients received an average of 3 laser 
treatments of which the decision was made at each follow up visit to treat if clinically 
indicated according to ETRDS guidelines. In the bevacizumab arm 42 eyes underwent 
injections at baseline, 6 and 12-week time points. Follow up was done every 6 weeks 
with subsequent injections guided by OCT-based protocol with patients receiving an 
average of 9 injections.  At each follow up BCVA was measured.  
In this study dichotomous data was utilized with intention-to-treat analysis. The 
relative benefit increase (RBI), absolute benefit increase (ABI), and numbers needed to 
treat (NNT) were calculated using efficacy rates from the bevacizumab and laser therapy 
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arms of the trial. These values we derived from experimental event rate (EER) and 
controlled event rate (CER) using clinical success percentages defined as gaining greater 
than 10 ETRDS letters from baseline.  These results are summarized in Table 2. All 
statistical analysis was performed with a confidence interval (CI) of 95%.  The 
bevacizumab group not only had a higher clinical success rate, but also at the 12-month 
time point the mean change in BCVA yielded a P value of 0.002. Two patients in the 
laser arm did not complete the 12-month follow up, however their 32-week data was 
carried forward in the intention-to-treat analysis. 
Table 2:  Treatment versus Control Improvement in BCVA – 12 Month 
 CER EER RBI ABI NNT P-Value 
% patients 
gaining >10 
letters  
0.079 0.31 2.92 0.23 4.3 0.01 
 
In Rajendram et al, the same 80 eyes from Michaelides et al were continued to a 
24-month time point. Fifteen patients did not enter the second year of the study, therefore 
demographic and heath characteristics were compared among the remaining participants 
to assure there were still no significant differences.  In the laser arm 37 patients received 
an average of 1 additional treatment and were followed up at 4-month intervals.  In the 
bevacizumab arm 28 patients received an average of 1 additional intravitreal injection 
and were followed up at 6-week intervals. The decision to undergo re-treatment was 
guided by the same protocols as the previous study and BCVA was measured at each 
follow up.  
The same intention-to-treat analysis with dichotomous data was carried through to 
the 24-month time point. Experimental event rate (EER) and controlled event rate (CER) 
were calculated using clinical success percentages defined as gaining greater than 10 
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ETRDS letters from baseline.  The results are summarized in Table 3. All statistical 
analysis was performed with a confidence interval (CI) of 95%.  In the bevacizumab 
group at 2 years the percentage of patients with visual improvement was 49% compared 
to 7% in the laser group, continuing the trend from the previous study. The change in 
BCVA from baseline was a mean gain of 8.6 letters for the bevacizumab group versus a 
mean loss of 0.5 letters in the laser group reaching statistical significance (P = 0.05).  
Table 3:  Treatment versus Control Improvement in BCVA – 24 Month 
 CER EER RBI ABI NNT P-Value 
% patients 
gaining >10 
letters  
0.07 0.49 6 0.42 2.4 0.001 
 
In Solaiman et al 62 eyes were randomized into treatment and comparison groups. 
Among all participants, demographic characteristics of average age, duration of diabetes, 
BCVA, and extent of macular edema were similar between the two groups. Only stage of 
retinopathy varied significantly with 5 participants in the laser group with 
nonproliferative diabetic retinopathy (NPDR) versus 6 with proliferative diabetic 
retinopathy (PRD). In the bevacizumab group similar trends were noted with 6 
participants diagnosed with NPDR versus 5 with PDR.  In the laser arm 19 eyes 
underwent 1 laser therapy treatment at baseline and were follow up at 1, 3, and 6 month 
intervals. In the bevacizumab group 21 eyes received one intravitreal injection at baseline 
and were followed up at the same time intervals. BCVA was measured at all visits.  
Continuous data was reported, but could not be converted to dichotomous data. At 
the 1 month follow up the mean improvement in BCVA from baseline was 38% 
calculated using a paired t test. A P value of  < 0.05 was reported for the bevacizumab 
group with no significant differenced noted in the laser group.  At 3 months there was no 
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statistical significance in BCVA in either group and at 6 months both groups regress to 
approximately baseline values for visual acuity, all yielding a P value > 0.05.  The results 
are summarized in Table 4. This data suggests that improvement in BVCA was 
transiently seen at only 1 month with intravitreal bevacizumab injections.  
Table 4: Change Over Time in Mean BCVA   
Duration Laser Therapy Bevacizumab 
Injections 
P-Values 
Baseline 0.84 0.84  
1 month  0.83 0.52 P < 0.05 
3 months  0.75 0.71 P > 0.05 
6 months  0.85 0.82 P > 0.05 
 
Discussion 
This systematic review analyzed three RCT’s to determine if intravetrial 
bevacizumab injections are more effective than laser therapy at improving BCVA in 
patients with DME.  Overall the data demonstrates greater efficacy with repeated 
bevacizumab injections over laser therapy, which is the current standard of care. The data 
collected in two of the studies showed statistical significance at improving visual 
outcomes at 1 and 2 years.  
Bevacizumab was first introduced as a treatment for various neoplastic processes, 
most notably colorectal cancer. Due to its mechanism of action as a VEGF inhibitor its 
use began unlabeled for age-related macular degeneration. Bevacizumab has various 
black box warnings related to intravenous administration, but they do not apply to the 
local ocular injections. 9 Ophthalmic adverse events occur less that 2% of the time, most 
commonly vision loss due to endophthalmitis. There are no contraindications to this 
medications use, however the cost is significant at $761 per 4 mL without a generic 
available. 9 
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There were various limitations plaguing all three studies. All three trials recruited 
and tested a small sample of patients to investigate the treatment and comparison 
interventions. In Rajendram et al 15 patients did not wish to continue with the study 
illustrating the difficulty in maintaining a population over a long period of time that 
requires significant follow up. Another hindrance was the relatively short follow up 
period, ranging from 6 to 24 months, related to the disease process of macular edema.  
This decreases the strength of the finds in treatment of DME globally. Michaelides et al 
argues that due to the chronicity of DME intravitreal bevacizumab injections may be 
impractical. This is due to a combination of factors including cost and need for repeat 
injections to maintain positive visual outcomes. It is hopeful that the 24-month report 
showed a decreased frequency of injections was necessary to maintain visual acuity.  This 
could aid healthcare providers in choosing this as a treatment option for patients thereby 
greatly increasing their quality of life. 
Solaiman et al specifically had more limitations that the other trials. The study did 
not take into account cofounding factors such as degree of glycemic control, 
hypertension, and renal disease. All can impact the severity of DME, facilitate more rapid 
progression of the disease process, and indicate poor compliance practices with treatment 
regimens.  Another factor limiting the strength of the results was that both the treatment 
and comparison groups had a disproportionate amount of patients with NPDR. This stage 
of retinopathy is less sensitive to VEGF dependent factors suggesting bevacizumab 
would be less therapeutic thereby placing that group at a disadvantage. This study also 
had deficits in validity due to its weak statistical analysis. It lacked a confidence interval, 
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specific P values were not calculated, and analysis was not performed on an intention-to-
treat basis.  
Conclusion 
In conclusion, this systematic review of three RCT’s demonstrates that intravetrial 
bevacizumab injections are more effective than laser therapy at improving best-corrected 
visual acuity in adults with diabetic macular edema. The data collected in two of the 
studies showed statistical significance at improving and maintaining visual outcomes 
through to a 2-year time point. Laser therapy is the current standard of care and this new 
body of evidence suggests bevacizumab should be strongly considered for 
implementation early on in the disease process. Further studies are warranted to evaluate 
the synergistic effect of laser therapy combined with bevacizumab injections to improve 
visual acuity and halt further vision loss in this patient population.  
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